KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs
SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.
- Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal AntibodySeptember 16, 2020 - 8:08 am
- Kindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth ConferenceSeptember 9, 2020 - 8:06 am
- Kindred Biosciences Announces Second Quarter 2020 Financial ResultsAugust 5, 2020 - 4:06 pm
KindredBio proudly supports
Rabies Free Africa